Skip to main content
. 2015 Jan 27;12:5. doi: 10.1186/s12985-014-0237-5

Figure 2.

Figure 2

Effects of various concentrations of Virkon S in deactivating Tobacco mosaic virus (TMV) infectivity as assessed in bioassays through rub-inoculation upon exposure for 30 sec using Virkon S at 0.5% (left) with no protection, at 1% (middle) with partial protection, and at 2% (right) with full protection.